A Randomized, Double Blind, Parallel Group, Phase II/III, Multi-center Trial of Two Doses of ZD1839 (IressaTM) in Patients with Advanced NSCLC Who Have Failed at Least Two Previous Chemotherapy Regimens At Least One or Both Having Contained Platinum and a Taxane.
Study identifier:1839IL/0039
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Randomized, Double Blind, Parallel Group, Phase II/III, Multi-center Trial of Two Doses of ZD1839 (IressaTM) in Patients with Advanced NSCLC Who Have Failed at Least Two Previous Chemotherapy Regimens At Least One or Both Having Contained Platinum and a Taxane.
Medical condition
lung cancer
Phase
Phase 2
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Nov 2000
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
